AMA says CVS-Aetna deal conditions aren’t good enough

In the wake of the Department of Justice clearing the path for CVS Health to merge with Aetna in a $69 billion deal, the American Medical Association still doesn’t think the conditions mandated by the Justice Department go far enough to quell anticompetition fears.

Aetna is required to sell off its Medicare Part D prescription drug plan for the merger with CVS Health to go through, the DOJ mandated Wednesday.

Multiple associations, legislators and regulators have voiced their concerns over the deal, which is one of the biggest in the healthcare space and brings together the nation’s largest pharmacy retailer and the third largest health insurance provider.

Aetna announced it agreed to sell its Medicare Part D business to Wellcare Health Plans last month. The Justice Department gave its preliminary approval for the deal to move forward on Wednesday with the caveat that Aetna complete its divestiture.

“While the AMA welcomes the U.S. Department of Justice (DOJ) requiring Aetna to divest its Medicare Part D drug plan business, we are disappointed that the DOJ did not go further by blocking the CVS-Aetna merger,” AMA said in a statement.

AMA voiced its opposition to the CVS-Aetna deal in August, urging regulators to block the merger over anti-competition concerns.

“We now urge the DOJ and state antitrust enforcers to monitor the post-merger effects of the Aetna acquisition by CVS Health on highly concentrated markets in pharmaceutical benefit management services, health insurance, retail pharmacy and specialty pharmacy,” AMA said Wednesday.

AMA is the nation’s largest association of physicians and medical students and was founded in 1847.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.